Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
bullous disease of the skin. First-line treatment of systemic corticosteroids may cause …

Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders
characterized by the production of autoantibodies against adhesion molecules of the skin …

Purpose Patients with chronic spontaneous urticaria (CSU) have an increased risk for
comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we …

The presence of autoreactive antibodies is a hallmark of many autoimmune diseases. The
effector functions of (auto) antibodies are determined by their constant domain, which …

The advent of immune checkpoint inhibition represents a paradigm shift in the treatment of
an increasing number of cancers. However, the incredible therapeutic promise of …

Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable
clarification of the mechanisms of immune regulation in the skin. Pemphigus and …

Importance Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP).
However, its effectiveness and safety have yet to be confirmed in a large-scale study …

Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of
programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors …

Simple Summary This article investigates the cutaneous adverse immune effects induced by
immune checkpoint inhibitors. These drugs target proteins expressed on cancer cells that …